EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Boston Scientific Corp. (0HOY) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Boston Scientific Corp. $48.45, price $43.02, upside +12.6%, quality 66 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Industrials · GB · Home US

BS Some data Sep 24, 2026

Boston Scientific Corp.

0HOY · LSE

UndervaluedQuality growthThe stock appears undervalued with acceptable quality.

✓Fair value $48.45 · Undervalued (+12.6%)
✓Quality 66/100
✓Healthy Growth (revenue 5y +15.2 %/yr)
✓Solidly profitable · 17.3% net margin (TTM)
✓Low debt · generates free cash flow
✓Ranks above peers (8/9)
!Moderate moat 64/100
!Evidence only medium, so the estimate is less certain
Watch Boston Scientific Corp. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$108.24 $30.65 Fair Value $48.45 May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $30.65 – $108.24 · fair‑value band $32.64 – $62.76 · the $43.02 price screens below the $48.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow Boston Scientific in your weekly email

Every Wednesday you see whether Boston Scientific is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.

Show more

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Stock analysis

Boston Scientific Corp. (0HOY) currently trades at $43.02, while our model-based Fair Value estimate is $48.45, implying the stock looks roughly 11.2% undervalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $49.31 per share, and 11 of the 24 models we run sit above the $43.02 price.

Bear case: the Asset-Based group reads lowest at $11.73, and 13 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: $32.64 (bear) to $62.76 (bull), the price of $43.02 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 66/100 (solid quality), in the Industrials sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Boston Scientific Corp. reported revenue of $20.1B in FY2025 versus $11.9B in FY2021, a compound +14.0%/yr. Reported net income was $2.9B in FY2025, compounding +29.1%/yr from FY2021.

Key figures

Market cap $64.3B · P/E ratio 0.8 · P/S ratio 0.12 · EPS (TTM) $0.5300 · Net margin 14.4% · Return on equity 14.7% · Return on assets (EBIT) 6.8% · Operating margin 20.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades about 59% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Industrials peers we cover trades at 6% fair-value upside, at 13%, 0HOY screens cheaper than that median.

Fair Value models

Bear $32.64 Fair Value $48.45 Bull $62.76
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.4008 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $29.45 $55.02 $97.21 77
Growth DCF $29.19 $52.57 $89.77 76
EPV $17.73 $21.34 $24.45 74
All 24 models by family
DCF Models
FCF DCF $29.45 $55.02 $97.21 77
Owner Earnings $27.00 $50.77 $89.98 73
5Y Revenue Exit $18.41 $32.87 $51.90 71
5Y EBITDA Exit $29.37 $55.23 $87.30 73
5Y P/E Exit $26.47 $49.31 $75.05 69
10Y Revenue Exit $21.39 $36.13 $57.59 65
10Y EBITDA Exit $29.05 $52.05 $86.27 66
10Y P/E Exit $27.18 $47.84 $76.35 62
Earnings-Based
Graham-Dodd $14.18 $63.46 $86.96 64
Lynch FV $16.51 $23.59 $30.66 61
PEG = 1.0 $16.51 $23.59 $30.66 57
EPV $17.73 $21.34 $24.45 74
Multiples
P/E Multiple $32.85 $43.80 $54.75 63
P/S Multiple $21.76 $29.01 $36.27 58
P/B Multiple $26.59 $35.45 $44.32 55
EV/EBIT $31.47 $43.66 $55.86 66
EV/EBITDA $32.50 $45.04 $57.58 67
EV/Revenue $13.16 $20.99 $28.83 53
Asset-Based
NCAV (Graham) $8.76 $11.73 $17.51 54
Growth DCF
Growth DCF $29.19 $52.57 $89.77 76
Rev-Margin DCF $18.41 $32.83 $51.29 71
Economic Profit
Residual Income $15.96 $18.52 $25.28 71
ROIC Compounder $17.84 $25.04 $34.10 71
Growth Earnings
Growth-Adj P/E $26.93 $38.46 $50.00 67

Open the full fair value analysis →

Notify me when 0HOY reaches fair value

Put 0HOY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 66/100

Of which business quality 64 · Market factors (momentum, volatility) 28

Profitability 49
Margins and returns on capital today
Quality Growth 64
Are margins and returns improving?
Cashflow 76
Earnings quality: real cash, not paper profit
Fin. Strength 64
Balance sheet, leverage, solvency risk
Investment 60
Disciplined investing over empire-building
Low Volatility 72
Calm price path (market factor)
Momentum 15
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 72
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+19.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.2%
Start year 2020 (pandemic). Over 10 years: +10.4% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.2%
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+30.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year+30.4%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−1.0% vs 22.6%, slowing
Profit margin 2019 to 2024 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 16%
2025 sits 77% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+12.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +9.8% a year for the price and +4.6% for the forecasts.
Forecast 2026 (sales)+7.5%
Forecast 2027 (sales)+8.1%
Projected 2028 (sales)+7.4%
Projected 2029 (sales)+6.6%
Projected 2030 (sales)+5.8%

Watch 0HOY, get fair value alerts →

Compare Boston Scientific Corp. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 349 stocks

Beats the industry median on 8/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 66 · Top 25%
Fair Value upside +12.6% · Above median
Profitability
Return on equity (TTM) 14.7% · Top 25%
Return on assets 6.1% · Top 25%
Net margin (TTM) 17.3% · Top 25%
Operating margin (TTM) 20.6% · Top 25%
Growth and dividend
Revenue growth 11.6% · Above median
Balance sheet
Debt / equity 0.38× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 0.8× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)50 · sector 9
FUTURE (revenue growth)58 · sector 32
PAST (return on equity)59 · sector 11
HEALTH (low debt)81 · sector 97
DIVIDEND (yield)0 · sector 39

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $98.83 $74.79 −24%
Medtronic plc MDT $87.09 $65.61 −25%
Stryker Corporation SYK $278.77 $306.65 +10%
Edwards Lifesciences Corporation EW $85.19 $81.94 −4%
Siemens Healthineers AG SHL €37.86 €35.19 −7%
DexCom, Inc DXCM $86.68 $95.35 +10%
GE HealthCare Technologies Inc GEHC $66.63 $70.37 +6%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥153.86 ¥169.25 +10%
Koninklijke Philips N.V PHIA €21.87 €15.23 −30%
STERIS plc STE $208.93 $229.82 +10%

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Boston Scientific Corp. · Fair Value
$48.45 +11%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Boston Scientific Corp. Fair Value". https://www.fairvalue-calculator.com/stock/0HOY

Frequently asked questions

Is Boston Scientific Corp. (0HOY) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $48.45 versus a price of $43.02, about +13% upside (undervalued).
What is the fair value of 0HOY?
Our model-based fair value for Boston Scientific Corp. is $48.45 (as of Sep 24, 2026), built from audited fundamentals. The current price: $43.02.
What is the quality score of 0HOY?
Boston Scientific Corp. has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Boston Scientific Corp. (0HOY)?
Our model-based price target is the fair value of $48.45 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $32.64, optimistic scenario $62.76. It is a calculation from audited fundamentals, not an analyst target.
What is the Boston Scientific Corp. stock forecast for 2026?
Our models put fair value at $48.45, about +13% upside versus a price of $43.02 (undervalued). Cautious scenario $32.64, optimistic scenario $62.76. The calculation is refreshed regularly with new filings.
What is the revenue of Boston Scientific Corp. (0HOY)?
Boston Scientific Corp. reported trailing-twelve-month revenue of about $20.6B (latest available figure, as of Sep 24, 2026).
What growth is priced into Boston Scientific Corp. (0HOY)?
For today's price to be fair in a discounted-cash-flow model, Boston Scientific Corp. would have to grow free cash flow by +12.4 % per year for five years (discount rate 9.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +15.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0HOY use?
Our models discount Boston Scientific Corp. at 9.2 %: a base by market capitalisation (unknown), damped by beta 0.58, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Boston Scientific Corp. that is +12.4 % per year a year over ten years, using the same discount rate (9.2 %) and the same formula as our fair value.
How much growth has Boston Scientific Corp. (0HOY) delivered so far?
Over the past 5 years revenue at Boston Scientific Corp. grew +15.2 % a year. The price currently implies +12.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Boston Scientific Corp. (0HOY) growing?
The median revenue growth in the sector is +7.2 % a year. That is the yardstick for the growth priced into Boston Scientific Corp. (+12.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Boston Scientific Corp. (0HOY)?
The free-cash-flow yield on the price is 4.30 %: that much free cash flow Boston Scientific Corp. produces per unit of market value. When it exceeds the discount rate of our models (9.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Boston Scientific Corp. (0HOY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Boston Scientific Corp. it is $48.45 per share (as of Sep 24, 2026), against a price of $43.02. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Boston Scientific Corp. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0HOY trades below its calculated fair value: price $43.02, fair value $48.45, a gap of about +13% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0HOY?
No. The price is what the market pays today ($43.02); the fair value is what the company's own numbers justify ($48.45). For Boston Scientific Corp. the two are $5.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is Boston Scientific Corp. worth?
The market values Boston Scientific Corp. at about $64.3B (market capitalisation, as of Sep 24, 2026). Per share that is $43.02; our models calculate a fair value of $48.45 per share.
What do the bullish and bearish scenarios say about 0HOY?
Our models span a range for Boston Scientific Corp.: cautious scenario $32.64, base $48.45, optimistic $62.76 per share (as of Sep 24, 2026, price $43.02). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 0HOY?
Boston Scientific Corp. trades at a price-to-earnings ratio of 0.8 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $48.45 is built from several models across several years.
How solid is the balance sheet of Boston Scientific Corp. (0HOY)?
Balance-sheet figures for Boston Scientific Corp. (as of Sep 24, 2026): return on equity 14.7%, debt of 0.38 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is 0HOY from its 52-week high?
Boston Scientific Corp. trades at $43.02, about 59% below its 52-week high of $105.57 and at the low of $42.83 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $48.45 is for.
Which stocks are comparable to Boston Scientific Corp.?
From the same area (Industrials) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Edwards Lifesciences Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Boston Scientific Corp. stock attractive at the current price?
The data as of Sep 24, 2026: price $43.02, calculated fair value $48.45 (+13%), Quality Score 66/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0HOY calculated?
We run Boston Scientific Corp. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $48.45, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Boston Scientific Corp. currently trades 11 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Boston Scientific Corp. (0HOY)?
The closing price on Oct 2, 2026 was $43.02. Our model-based fair value is $48.45, about +13% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Boston Scientific Corp. right now?
A fairly wide model range ($32.64 to $62.76) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Boston Scientific Corp.

How large is the market capitalisation of Boston Scientific Corp. (0HOY)?
The market capitalisation of Boston Scientific Corp. is $64.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Boston Scientific Corp. (0HOY)?
The price-to-sales ratio of Boston Scientific Corp. is 0.12 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Boston Scientific Corp. (0HOY)?
Earnings per share at Boston Scientific Corp. are $0.5300 (price ÷ EPS = P/E 0.8). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Boston Scientific Corp. (0HOY)?
The net margin of Boston Scientific Corp. is 14.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Boston Scientific Corp. (0HOY)?
The return on equity (ROE) of Boston Scientific Corp. is 14.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Boston Scientific Corp. (0HOY)?
On an EBIT basis the return on assets of Boston Scientific Corp. is 6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Boston Scientific Corp. (0HOY)?
The operating margin of Boston Scientific Corp. is 20.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Boston Scientific Corp. (0HOY)?
Revenue at Boston Scientific Corp. is growing +11.6% versus a year earlier (3y avg +16.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Boston Scientific Corp. (0HOY)?
Earnings per share at Boston Scientific Corp. are growing +100% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Boston Scientific Corp. (0HOY) carry?
The net debt of Boston Scientific Corp. is $10.4B (fiscal year 2025, ≈ 2.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Boston Scientific Corp. in the live analysis

One click puts Boston Scientific Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.